CDKN1A Knockout cell line (AC16)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

CDKN1A (cyclin dependent kinase inhibitor 1A) encodes a potent cyclin-dependent kinase inhibitor that regulates cell-cycle progression at the G1 phase. The protein inhibits cyclin-CDK2 and cyclin-CDK4 complexes and mediates p53-dependent G1 arrest in response to cellular stress. CDKN1A also interacts with proliferating cell nuclear antigen and contributes to regulation of DNA replication and DNA damage repair, linking cell-cycle control with genome maintenance and stress responses.

Human cardiac ventricular cells are represented by AC16, an immortalized cell line derived from primary human ventricular tissue. The cells were generated by fusion of primary adult ventricular cardiomyocytes with a human fibroblast-like cell line carrying a temperature-sensitive SV40 large T antigen. AC16 exhibits cardiac-related characteristics and is used as an in vitro model for studies of human cardiomyocyte biology.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.